Regulatory Submission Blog

BiotechCentrusCROPharmaceuticalPre-ClinicalRegulatory SubmissionSENDSEND Advantage ServicesSensible SEND

Is SEND the key to unlocking Historical Control Data?

Marc Ellison

With SEND enabling access to standardized data, the long-envisioned potential of Historical Control Data systems is becoming a practical reality.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

Is the latest Technical Conformance Guide update, the most important to date?

Marc Ellison

The FDA’s latest guidance makes one thing clear: if a study informs clinical safety and can be rendered in SEND, it likely should be, making “Does this need SEND?” a tougher question than ever.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

Why Define-XML files give me the Happy Mondays

Marc Ellison

Much like Bez from the Happy Mondays, the Define-XML file may seem puzzling, but without it, the SEND package just isn’t complete, and its value is becoming harder to ignore.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

Can SEND datasets be fully compliant…but still wrong?

Marc Ellison

Compliance with SEND is crucial, but correctness is king. A perfectly formatted dataset means little if the values don’t reflect the actual study data.

BiotechCentrusCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

Did you see the recent paper from the JPMA SEND Taskforce Team?

Marc Ellison

SEND works well for single study review, but variability across datasets limits its value for cross-study analysis, something the JPMA’s recent paper explores in compelling detail.

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.